On June 10, 2025, Travere Therapeutics, Inc. announced that its Compensation Committee has granted inducement equity awards to 15 new employees. These awards consist of restricted stock units (RSUs) covering a total of 81,100 shares of the company's common stock. The RSUs, granted under Nasdaq Listing Rule 5635(c)(4), are part of an agreement to attract new talent and are issued outside of the company's 2018 Equity Incentive Plan. The RSUs will vest over four years, with 25% of the shares vesting on each anniversary of the grant date, contingent upon the employees maintaining their service with Travere.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.